Overview

The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Status:
Active, not recruiting

Trial end date:
2021-02-28

Target enrollment:

Participant gender:

Summary

Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and ATRA in patients with steroid-resistant/relapsed ITP.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Collaborators:

Beijing Hospital
Beijing Tongren Hospital
Navy General Hospital, Beijing

Treatments:

Rituximab
Tretinoin